This study, called the UAdapt Trial, is for men with early-stage prostate cancer. It's looking at different ways to treat the cancer using radiation therapy, specifically a single high dose of radiation (called SBRT) delivered only to the tumor within the prostate, not the whole prostate. The study is also exploring if adding a short course of hormone therapy (ultra-short-term androgen deprivation therapy or uSTADT) with Relugolix can make the treatment more effective while keeping side effects low. Researchers also want to see if this type of radiation can help your immune system fight the cancer. The study aims to see how many patients have their cancer return or spread within about 14 months. You may be able to join if you are a man between 35 and 85 years old with biopsy-confirmed prostate cancer that is T1-T3 stage. The current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 130 participants. It is testing different radiation approaches (FTLEAD and HypoLEAD) with or without the drug Relugolix or standard hormone therapy.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 14 months to assess for biochemical disease failure and clinical disease failure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.